BOT - Anything but charting, page-7861

The share price at the time of previous FDA decision was about 20c, usually with a 50% discount. The share price has only inches up a couple of pips, despite the instruction for use. Still leaves a ‘bot’ of upside with time to go before the resubmission decision, which doesn’t have an absolute guarantee.

in terms of value if you use Euroz figures as a basis and reverse engineer, it’s sitting at bear case of 0.5% market share with 50% approval discount. A few catalysts to set the scene, approval before-June-after it’s hard to judge exact timing, so expecting FOMO in May.

Sales if approved Q1 and Q2 will be telling of where this is headed. Enjoy!